Ultragenyx (RARE) Peer Comparison

$14.22

$-0.56 (-3.76%)

As on 25-Sep-2026 13:37EDT

Market cap

$1,431 Mln

Revenue (TTM)

$717 Mln

P/E Ratio

--

P/B Ratio

19.7

Div. Yield

0 %

Edit

	Ultragenyx (RARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	1,431	17,091	15,572	14,461	12,763
Revenue ($ Mln)	717	2,782	1,054	2,436	1,664
Net Profit ($ Mln)	-586.41	491.50	755.85	860.62	413.60
Net Margin (%)	-81.79	17.67	71.69	35.33	24.86
RoE (%)	--	110.09	--	42.98	430.03
Price to Earnings	--	35.98	18.45	18.35	32.13
Price-To-Book	19.68	39.58	9.49	7.84	86.73

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Ultragenyx (RARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Operating Revenue	716.93	2,782.29	1,054.37	2,435.92	1,663.74
Cost of Revenue	120.99	1,982.07	103.47	85.67	363.07
Gross Profit	564.00	760.62	588.53	2,236.43	1,091.18
Operating Expenses	1,124.83	216.81	841.45	1,378.74	356.18
Operating Profit (EBIT)	-528.89	583.40	109.45	971.51	944.49
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-582.54	598.92	101.11	1,035.47	583.34
Provision for Tax	3.87	107.42	-654.74	174.84	169.74
Profit after Tax (Net Income)	-586.41	491.50	755.85	860.62	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Ultragenyx (RARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Shareholder's Funds	-291.00	433.86	1,435.90	1,843.76	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	1,197.00	187.89	384.48	288.55	2,089.43
Current Liabilities	351.00	1,435.43	464.70	361.93	344.44
Total Liabilities	1,532.00	1,975.47	1,302.02	2,844.42	2,525.32

Assets ($ Mln)

	Ultragenyx (RARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Non-Current Assets	658.00	1,006.90	895.24	1,243.41	1,644.38
Current Assets	606.00	1,050.29	1,389.84	1,250.82	933.02
Total Assets	1,532.00	1,975.47	1,302.02	2,844.42	2,525.32
Total Debt*	1,202.00	120.10	449.89	165.93	2,146.65
Net Current Assets	255.00	-385.14	925.52	888.90	588.59

Cashflow ($ Mln)

	Ultragenyx (RARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-466.00	713.22	51.77	884.27	651.56
Cash Flow from Investing Activities	236.00	-31.14	-8.15	350.44	-545.81
Cash from Financing Activities	478.00	-860.39	34.89	-969.59	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Ultragenyx (RARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
ROCE (%)	-77.10	53.56	-30.01	32.82	15.61
ROE (%)	-656.03	110.09	163.18	42.98	430.03
ROA (%)	-36.49	15.64	31.68	29.32	16.19
EBIT Margin (%)	-70.63	21.13	5.73	31.04	36.28
Net Margin (%)	-81.79	17.67	71.69	35.33	24.86
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Ultragenyx (RARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	17.50	24.67	114.85	9.23	41.15
EBIT Growth (%)	-7.57	18.70	136.39	-3.99	-14.99
Net Profit Growth (%)	-10.04	17.50	378.76	42.89	-25.78
EPS Growth (%)	-5.65	26.84	353.27	50.42	-23.48
Book Value Growth (%)	-285.86	164.02	816.12	-0.70	-55.81

Valuation Ratios

	Ultragenyx (RARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Price / Earnings	-4.00	36.06	-59.76	15.79	24.99
Price / Book Value	-28.72	35.44	-80.42	5.72	162.23
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-6.08	28.08	-121.54	12.44	17.31
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Ultragenyx (RARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debt to Equity	0.00	0.00	0.27	0.00	13.50
Short term debt to equity ratio	-0.26	0.00	0.05	0.00	1.46
Current Ratio	1.73	0.73	2.99	3.46	2.71
Quick Ratio	1.56	0.73	2.32	3.38	2.31
Interest Coverage	-6.65	--	1.62	--	29.73

Operating Efficiency Ratios

	Ultragenyx (RARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	27.90	15.88	21.25	13.74	27.40
Asset Turnover	0.45	0.89	0.44	0.83	0.65
Receivable days	76.20	50.42	85.52	43.48	98.04
Inventory Days	162.53	--	1,056.70	96.17	190.34
Payable days	116.87	6.26	331.01	147.97	18.62
Cash Conversion Cycle	121.86	--	811.21	-8.32	269.75

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly